Aetna modified CPB 0719 covering fluocinolone acetonide intravitreal implants (Retisert, Iluvien, and Yutiq), effective September 26, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its coverage policy for fluocinolone acetonide intravitreal implants under CPB 0719. This policy governs three drugs—Retisert (J7311), Iluvien (J7313), and Yutiq (J7314)—used for chronic non-infectious uveitis and diabetic macular edema. The update clarifies medical necessity criteria and contraindications that directly affect whether your claims for CPT 67027 and 67028 get paid or denied.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Fluocinolone Acetonide Intravitreal Implant (Retisert and Iluvien) |
| Policy Code | CPB 0719 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Ophthalmology, Retina Specialists, Endocrinology (DME-adjacent billing for diabetic complications) |
| Key Action | Audit active claims and prior auth requests for J7311, J7313, and J7314 against updated contraindication criteria before billing |
Aetna Fluocinolone Acetonide Intravitreal Implant Coverage Criteria and Medical Necessity Requirements 2025
The Aetna fluocinolone acetonide intravitreal implant coverage policy splits across three drugs and two indications. Get these criteria wrong and you're looking at a claim denial before the EOB hits your desk.
Retisert and Yutiq (J7311 and J7314)
Aetna covers Retisert (fluocinolone acetonide 0.59 mg, billed as J7311) and Yutiq (fluocinolone acetonide 0.18 mg, billed as J7314) for chronic non-infectious uveitis affecting the posterior segment of the eye. This includes birdshot chorioretinopathy. Coverage requires that the patient failed corticosteroid or immunosuppressive therapy first. "Does not respond to or is intolerant to conventional treatment" is the exact language—document both options in your records, because "intolerant" is a separate path from "failed."
Active ocular or periocular infections are a hard contraindication for both drugs. Aetna calls these not medically necessary under that condition. If your documentation shows active infection at the time of implant, expect a denial.
Iluvien (J7313)
Iluvien has two covered indications under this coverage policy.
Diabetic macular edema: Aetna covers Iluvien (J7313) for diabetic macular edema when the patient had a prior course of corticosteroids and did not have a clinically significant rise in intraocular pressure. That IOP history is the pivot point—it's the difference between a covered claim and a not-medically-necessary denial. Pull IOP measurements from the chart before you submit.
Chronic non-infectious uveitis: Iluvien also covers chronic non-infectious uveitis affecting the posterior segment. The policy doesn't repeat the failed-conventional-treatment requirement here for Iluvien the way it does for Retisert and Yutiq—but document treatment history anyway. Auditors will look for it.
Iluvien contraindications: Two conditions make Iluvien not medically necessary under this policy. Active ocular or periocular infections disqualify the patient. Glaucoma with a cup-to-disc ratio greater than 0.8 is the second disqualifier. That cup-to-disc threshold is specific—make sure your ophthalmology team is capturing and documenting that measurement.
Prior Authorization
This policy doesn't spell out a prior authorization requirement by name, but the criteria are detailed enough that prior auth is almost certainly triggered for these drugs. Retisert, Yutiq, and Iluvien are specialty pharmaceuticals delivered via surgical implant. If your practice isn't verifying prior auth status for J7311, J7313, and J7314 on every Aetna patient, start now. Talk to your billing consultant if you're unsure how Aetna routes these through pharmacy versus medical benefit.
Aetna Fluocinolone Acetonide Intravitreal Implant Exclusions and Non-Covered Indications
Active infections rule out coverage for all three drugs. The policy draws a hard line here—both Retisert/Yutiq and Iluvien are explicitly called not medically necessary when active ocular or periocular infection is present.
For Iluvien specifically, glaucoma with a cup-to-disc ratio greater than 0.8 is a standalone contraindication. This is the kind of specific clinical threshold that gets missed when chart documentation is incomplete. If the ophthalmologist doesn't record that measurement, your claim is exposed.
CPT 65770 (keratoprosthesis) appears in the policy's code set but sits in the "not covered for indications listed in the CPB" group. Don't bill 65770 under CPB 0719 expecting coverage—it won't fly. Similarly, HCPCS C1814 (retinal tamponade device, silicone oil) is listed as not covered for these indications.
Coverage Indications at a Glance
| Indication | Drug | Status | Key Codes | Notes |
|---|---|---|---|---|
| Chronic non-infectious uveitis (posterior segment), including birdshot chorioretinopathy | Retisert, Yutiq | Covered | J7311, J7314, CPT 67027, 67028 | Must fail corticosteroids or immunosuppressives first; no active infection |
| Chronic non-infectious uveitis (posterior segment) | Iluvien | Covered | J7313, CPT 67027, 67028 | No active infection; no glaucoma with C:D ratio >0.8 |
| Diabetic macular edema | Iluvien | Covered | J7313, CPT 67027, 67028 | Prior corticosteroid course required; no clinically significant IOP rise |
| Any indication with active ocular or periocular infection | Retisert, Yutiq, Iluvien | Not Covered | J7311, J7313, J7314 | Hard contraindication for all three drugs |
| Any indication with glaucoma (C:D ratio >0.8) | Iluvien | Not Covered | J7313 | Iluvien-specific contraindication |
| Keratoprosthesis | N/A | Not Covered | CPT 65770 | Not covered for any indication in CPB 0719 |
| Retinal tamponade (silicone oil) | N/A | Not Covered | C1814 | Not covered for any indication in CPB 0719 |
Aetna Fluocinolone Acetonide Intravitreal Implant Billing Guidelines and Action Items 2025
The fluocinolone acetonide intravitreal implant billing requirements under CPB 0719 are specific enough that generic workflows will miss them. Here's what to do before the September 26, 2025 effective date hits your open claims.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for J7311, J7313, and J7314 now. Make sure every active Aetna claim for these HCPCS codes has documentation that matches the updated criteria. For J7311 and J7314, you need documented failure of or intolerance to corticosteroids or immunosuppressives. For J7313 on DME, you need documented prior corticosteroid use and IOP history. |
| 2 | Add cup-to-disc ratio to your Iluvien (J7313) documentation checklist. This is the detail most practices will miss. Glaucoma with a C:D ratio greater than 0.8 disqualifies the patient for Iluvien coverage. If it's not in the chart, you can't prove compliance—and Aetna will deny on medical necessity grounds. |
| 3 | Verify active infection status is documented at time of service. For all three drugs, active ocular or periocular infection is a disqualifier. Your pre-op or pre-injection documentation should explicitly note infection status. "No active infection" should appear in the chart, not just be implied. |
| 4 | Confirm prior authorization status before every procedure involving CPT 67027. The implantation code (67027) carries the highest reimbursement exposure. A denied claim at that level hurts. Don't assume a prior auth from 90 days ago covers a new implant—verify current status on Aetna's portal. |
| 5 | Pull the ICD-10 diagnosis code list for diabetic macular edema claims carefully. The policy includes hundreds of diabetic retinopathy codes (E08.311 through ranges in E09, E10, E11, E13 series). Use the most specific code available. An unspecified diabetes code with macular edema when a more specific code exists is a soft target for audit. |
| 6 | Remove CPT 65770 and HCPCS C1814 from any CPB 0719 billing templates. These codes are explicitly not covered under this policy. If they appear in your charge capture templates alongside J7311, J7313, or J7314, clean them out now. Bundling or accidental submission will trigger a denial. |
| 7 | Talk to your compliance officer if your practice treats birdshot chorioretinopathy. This is a niche indication covered under Retisert and Yutiq, but it requires the same failed-conventional-treatment documentation as other uveitis indications. The diagnosis codes in the ICD-10 list for this indication warrant a separate documentation protocol review. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Fluocinolone Acetonide Intravitreal Implants Under CPB 0719
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 67027 | CPT | Implantation of intravitreal drug delivery system (e.g., ganciclovir implant), includes concomitant vitrectomy |
| 67028 | CPT | Intravitreal injection of a pharmacologic agent (separate procedure) |
Not Covered Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 65770 | CPT | Keratoprosthesis | Not covered for indications listed in CPB 0719 |
| C1814 | HCPCS | Retinal tamponade device, silicone oil | Not covered for indications listed in CPB 0719 |
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J7311 | HCPCS | Injection, fluocinolone acetonide, intravitreal implant (Retisert), 0.01 mg |
| J7313 | HCPCS | Injection, fluocinolone acetonide intravitreal implant (Iluvien), 0.01 mg |
| J7314 | HCPCS | Injection, fluocinolone acetonide, intravitreal implant (Yutiq), 0.01 mg |
Key ICD-10-CM Diagnosis Codes
The full ICD-10 list under CPB 0719 runs nearly 1,000 codes. Below are the primary categories your billing team should map to each covered indication. Use the most specific code available.
Diabetic Macular Edema (Iluvien — J7313)
| Code | Description |
|---|---|
| E08.311 | Diabetes due to underlying condition with unspecified diabetic retinopathy with macular edema |
| E08.3211–E08.3219 | Diabetes due to underlying condition with mild nonproliferative retinopathy with macular edema (laterality-specific) |
| E08.3311–E08.3319 | Diabetes due to underlying condition with moderate nonproliferative retinopathy with macular edema |
| E08.3411–E08.3419 | Diabetes due to underlying condition with severe nonproliferative retinopathy with macular edema |
| E08.41 | Diabetes due to underlying condition with diabetic mononeuropathy (macular edema variant) |
| E08.51 | Diabetes due to underlying condition with proliferative diabetic retinopathy with macular edema |
| E09.311 | Drug or chemical induced diabetes with unspecified diabetic retinopathy with macular edema |
| E09.3211–E09.3219 | Drug or chemical induced diabetes with mild nonproliferative retinopathy with macular edema |
| E09.3311–E09.3312 | Drug or chemical induced diabetes with moderate nonproliferative retinopathy with macular edema |
| E09.3411–E09.3413 | Drug or chemical induced diabetes with severe nonproliferative retinopathy with macular edema |
Uveitis and Posterior Segment Conditions (Retisert, Yutiq, Iluvien)
| Code | Description |
|---|---|
| A52.71 | Late syphilitic oculopathy |
| B02.30–B02.39 | Zoster ocular disease (multiple laterality/manifestation codes) |
| C69.20–C69.22 | Malignant neoplasm of retina (paraneoplastic visual syndromes) |
| D48.7 | Neoplasm of uncertain behavior, other specified sites (diffuse uveal melanocytic proliferation) |
Active Infection Codes (Contraindicated — Do Not Submit as Primary)
| Code | Description |
|---|---|
| A54.30–A54.39 | Gonococcal infection of eye (multiple codes) |
| A71.0–A71.9 | Trachoma (multiple codes) |
| B30.0–B30.9 | Viral conjunctivitis (multiple codes) |
The full ICD-10 list includes 998 codes total. Pull the complete list from Aetna CPB 0719 and build a crosswalk for your most common diagnoses before the effective date of September 26, 2025.
Get the Full Picture for CPT 67027
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.